Evidence map›Paper›PMID 39534212›Full record

ArticleKidney international reports2024

Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory.

Barbara Cellini, Michelle A Baum, Yaacov Frishberg, Jaap W Groothoff, Peter C Harris, Sally A Hulton, Felix Knauf, John Knight, John C Lieske, W Todd Lowther and 5 more

Abstract read
In one paragraph

Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Synthesis andInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Barbara CelliniDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Michelle A BaumDepartment of Nephrology, Boston Children's Hospital, Boston, Massachusetts, USA.
Yaacov FrishbergDivision of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel.
Jaap W GroothoffDepartment of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, Amsterdam, the Netherlands.
Peter C HarrisDivision of Nephrology and Hypertension and Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA.
Sally A HultonDepartment of Nephrology, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, UK.
Felix KnaufDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
John KnightDepartment of Urology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
John C LieskeDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
W Todd LowtherCenter for Structural Biology, Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Shabbir MoochhalaUCL Department of Renal Medicine, Royal Free Hospital, London, UK.
Lama NazzalNephrology Division, NYU Langone Health and NYU Grossman School of Medicine, New York, New York, USA.
Gregory E TasianDivision of Pediatric Urology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Jonathan M WhittamoreCharles and Jane Pak Center for Mineral Metabolism and Clinical Research UT Southwestern Medical Center, Dallas, Texas, USA.
David J SasDivision of Pediatric Nephrology and Hypertension, Mayo Clinic Children's Center, Rochester, Minnesota, USA.

Funding

Coordinating Unit for the Innovative Science Accelerator ProgramU24DK128851 · NIDDK · AUGUSTA UNIVERSITY · PI MCINDOE, RICHARD A. · 2021 to 2025
$6.7M
Hydroxyproline Dehydrogenase Inhibitors for the Treatment of Primary HyperoxaluriaR01DK137305 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI W TODD LOWTHER · 2024 to 2026
$2.0M
Gut-kidney axis in enteric hyperoxaluriaR01DK129675 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NAZZAL, LAMA · 2021 to 2025
$1.7M
NIDDK NIH HHS R01 DK129675NIDDK NIH HHS R01 DK137305NIDDK NIH HHS U24 DK128851
6 · The paper itself

Abstract

Hyperoxaluria is a condition in which there is a pathologic abundance of oxalate in the urine through either hepatic overproduction (primary hyperoxaluria [PH]) or excessive enteric absorption of dietary oxalate (enteric hyperoxaluria [EH]). Severity can vary with the most severe forms causing kidney failure and extrarenal manifestations. To address the current challenges and innovations in hyperoxaluria, the 14th International Hyperoxaluria Workshop convened in Perugia, Italy, bringing together international experts for focused presentation and discussion. The objective of the following report was to disseminate an overview of the proceedings and provide substrate for further thought. The format of this paper follows the format of the meeting, addressing, "PH type 1" (PH1) first, followed by "surgery, genetics, and ethics in PH", then "PH types 2 and 3," (PH2 and PH3) and, finally, "EH." Each session began with presentations of the current clinical challenges, followed by discussion of the latest advances in basic and translational research, and concluded with interactive discussions about prioritizing the future of research in the field to best serve the need of the patients.

Identifiers

PMID39534212
PMCPMC11551133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.